3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Myelodysplastic Syndromes
2
Lung Neoplasms
2
Leukemia
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, Non-Hodgkin
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pembrolizumab
61
Cisplatin
45
Cetuximab
32
Radiotherapy
25
Nivolumab
22
Docetaxel
16
Radiotherapy, Intensity-Modulated
14
Paclitaxel
13
Carboplatin
13
durvalumab
11
Radiation
10
Fluorouracil
10
Magnetic Resonance Spectroscopy
9
Cyclophosphamide
9
fludarabine
8
Erlotinib Hydrochloride
8
budigalimab
7
Ipilimumab
7
atezolizumab
6
Radiosurgery
6
Gemcitabine
6
Drug Therapy
6
130-nm albumin-bound paclitaxel
6
tremelimumab
5
tislelizumab
5
spartalizumab
5
fludarabine phosphate
5
avelumab
5
Surgical Procedures, Operative
5
Specimen Handling
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Squamous Cell Carcinoma of Head and Neck
×
mocetinostat
×
Clear all
NCT02993991
2017-12-29
PRIMED-001
University Health Network, Toronto
Phase 1
Withdrawn